Indian generic drugmakers are delaying more investments in COVID-related drugs after making gains in the last two years, according to certain pharmaceutical industry insiders. BDR Pharmaceuticals’ managing director, Dharmesh Shah, stated that when COVID-19 cases start to decline, his company is not in a rush to introduce any new products. The number of daily COVID-19 cases […]

The post No Rush In Indian Generic Drug Firms To Offer COVID Products first appeared on World Pharma Today.